Assyro AI

FDA Orange Book · active-ingredient family

Rimegepant sulfate

Rimegepant sulfate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:NURTEC ODT · NDA 212728

1

Brand (NDA)

0

Generics (ANDA)

3

Listed patents

0

Exclusivity periods

Brand (NDA) products · tablet, orally disintegrating

ProductApplicantApplicationTEApproved
NURTEC ODTRLDPFIZERNDA 212728Feb 27, 2020

Listed patents (3)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8759372Feb 25, 2033in 6 yr 9 mo
SubstanceProduct
8314117Feb 27, 2034in 7 yr 10 mo
SubstanceProductU-2718
11083724Mar 25, 2039in 12 yr 11 mo
ProductU-2718

Rimegepant sulfate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.